Wells Fargo Maintains Overweight on C4 Therapeutics, Raises Price Target to $10
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Derek Archila maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and raises the price target from $5 to $10.
Wells Fargo analyst Derek Archila maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and raises the price target from $5 to $10.